# Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct05806060/  
OnCo record `nct05806060` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer is a phase 3, randomised interventional study registered as NCT05806060 by Fudan University, with a registry enrolment figure of 134 participants, started 2023-04-25 and due to reach its primary completion in 2026-05-01. Interventions recorded: VEGFR and TPC; TPC. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression) with BLIS subtype". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: BCTOP-T-M01
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05806060
- Phase: 3
- Setting: Precise Treatment for BLIS Subtype of Triple-negative Breast Cancer in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
- Sponsor: Fudan University
- Enrolled: 134

## Sources

- ClinicalTrials.gov NCT05806060: https://clinicaltrials.gov/study/NCT05806060

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05806060.json